Z S Zumsteg1, M Luu2, S Kim2, M Tighiouart2, A Mita3, K S Scher3, D J Lu4, S L Shiao4, J Mallen-St Clair5, A S Ho5. 1. Samuel Oschin Comprehensive Cancer Institute; Departments of Radiation Oncology. Electronic address: zachary.zumsteg@cshs.org. 2. Samuel Oschin Comprehensive Cancer Institute; Department of Biostatistics and Bioinformatics. 3. Samuel Oschin Comprehensive Cancer Institute; Division of Medical Oncology, Department of Medicine. 4. Samuel Oschin Comprehensive Cancer Institute; Departments of Radiation Oncology. 5. Samuel Oschin Comprehensive Cancer Institute; Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, USA.
Abstract
Background: Adjuvant chemoradiation (CRT) is standard for head and neck squamous cell carcinoma (HNSCC) patients with positive margins or extranodal extension (ENE) following surgery. However, emerging evidence suggests the number of positive lymph nodes (LNs) is the dominant determinant of survival in non-oropharyngeal HNSCC and thus may better identify those benefiting from treatment intensification. Patients and methods: Patients from the National Cancer Database diagnosed with non-oropharyngeal HNSCC (oral cavity, larynx, hypopharynx) between 2004 and 2014 and undergoing surgical resection, neck dissection, and postoperative radiotherapy (RT) were included. Multivariable regression with first-order interaction terms was used to model the interaction between postoperative CRT and continuous number of positive LNs with respect to overall survival. Results: In total, 7144 patients met inclusion criteria. In multivariable analysis, increasing number of positive LNs was associated with both increasing mortality (P < 0.001) and increasing benefit from postoperative CRT versus RT alone (interaction P < 0.001). While there was no benefit from postoperative CRT in patients with 0-2 LN+ [hazard ratio (HR) 0.96, 95% confidence interval (CI) 0.86-1.07, P = 0.47], increased benefit was seen in those with 3-5 LN+ (HR 0.84, 95% CI 0.70-1.00, P = 0.05) and those with ≥6 LN+ (HR 0.65, 95% CI 0.51-0.82, P < 0.001) in multivariable models. By contrast, margin status and ENE did not reliably identify patients benefitting from postoperative CRT based on statistical tests of interaction. Even in patients with ENE, positive margins, or both, only those with ≥6 LN+ had improved survival with postoperative CRT. Conclusion: Increasing metastatic nodal burden was associated with increased benefit from CRT compared with RT alone, surpassing conventional high-risk factors in identifying patients benefiting from CRT. Stratification by metastatic LN number may characterize a very-high-risk patient cohort best suited for treatment intensification.
Background: Adjuvant chemoradiation (CRT) is standard for head and neck squamous cell carcinoma (HNSCC) patients with positive margins or extranodal extension (ENE) following surgery. However, emerging evidence suggests the number of positive lymph nodes (LNs) is the dominant determinant of survival in non-oropharyngeal HNSCC and thus may better identify those benefiting from treatment intensification. Patients and methods: Patients from the National Cancer Database diagnosed with non-oropharyngeal HNSCC (oral cavity, larynx, hypopharynx) between 2004 and 2014 and undergoing surgical resection, neck dissection, and postoperative radiotherapy (RT) were included. Multivariable regression with first-order interaction terms was used to model the interaction between postoperative CRT and continuous number of positive LNs with respect to overall survival. Results: In total, 7144 patients met inclusion criteria. In multivariable analysis, increasing number of positive LNs was associated with both increasing mortality (P < 0.001) and increasing benefit from postoperative CRT versus RT alone (interaction P < 0.001). While there was no benefit from postoperative CRT in patients with 0-2 LN+ [hazard ratio (HR) 0.96, 95% confidence interval (CI) 0.86-1.07, P = 0.47], increased benefit was seen in those with 3-5 LN+ (HR 0.84, 95% CI 0.70-1.00, P = 0.05) and those with ≥6 LN+ (HR 0.65, 95% CI 0.51-0.82, P < 0.001) in multivariable models. By contrast, margin status and ENE did not reliably identify patients benefitting from postoperative CRT based on statistical tests of interaction. Even in patients with ENE, positive margins, or both, only those with ≥6 LN+ had improved survival with postoperative CRT. Conclusion: Increasing metastatic nodal burden was associated with increased benefit from CRT compared with RT alone, surpassing conventional high-risk factors in identifying patients benefiting from CRT. Stratification by metastatic LN number may characterize a very-high-risk patient cohort best suited for treatment intensification.
Authors: Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine van Glabbeke Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Brian O'Sullivan; Shao Hui Huang; Jie Su; Adam S Garden; Erich M Sturgis; Kristina Dahlstrom; Nancy Lee; Nadeem Riaz; Xin Pei; Shlomo A Koyfman; David Adelstein; Brian B Burkey; Jeppe Friborg; Claus A Kristensen; Anita B Gothelf; Frank Hoebers; Bernd Kremer; Ernst-Jan Speel; Daniel W Bowles; David Raben; Sana D Karam; Eugene Yu; Wei Xu Journal: Lancet Oncol Date: 2016-02-27 Impact factor: 41.316
Authors: David J Sher; Lucien Nedzi; Saad Khan; Randy Hughes; Baran D Sumer; Larry L Myers; John M Truelson; Matthew Koshy Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-08-01 Impact factor: 6.223
Authors: Allen S Ho; Sungjin Kim; Mourad Tighiouart; Cynthia Gudino; Alain Mita; Kevin S Scher; Anna Laury; Ravi Prasad; Stephen L Shiao; Nabilah Ali; Chrysanta Patio; Jon Mallen-St Clair; Jennifer E Van Eyk; Zachary S Zumsteg Journal: JAMA Oncol Date: 2018-07-01 Impact factor: 31.777
Authors: Cristina Valero; Daniella K Zanoni; Anjali Pillai; Bin Xu; Nora Katabi; Ronald A Ghossein; Ian Ganly; Luc G T Morris; Jatin P Shah; Richard J Wong; Snehal G Patel Journal: J Surg Oncol Date: 2020-09-24 Impact factor: 3.454
Authors: Jason Tasoulas; Nicholas R Lenze; Douglas Farquhar; Travis P Schrank; Colette Shen; M Ali Shazib; Bart Singer; Shetal Patel; Juneko E Grilley Olson; David N Hayes; Margaret L Gulley; Bhishamjit S Chera; Trevor Hackman; Andrew F Olshan; Jared Weiss; Siddharth Sheth Journal: Cancer Med Date: 2021-05-02 Impact factor: 4.452
Authors: Flora Yan; Hong Li; John R de Almeida; John M Kaczmar; Patrik Pipkorn; Joseph Zenga; Mary S Richardson; David M Neskey; Anand K Sharma; Terry A Day; Evan M Graboyes Journal: Otolaryngol Head Neck Surg Date: 2021-02-23 Impact factor: 5.591
Authors: Lorenzo Bresciani; Lorenzo Giannini; Alberto Paderno; Fabiola Incandela; Walter Fontanella; Davide Mattavelli; Cesare Piazza Journal: Front Oral Health Date: 2021-09-23